Laveta-A Capsule SR is a combination pharmaceutical formulation containing Levocetirizine 5 mg and Ambroxol 75 mg, designed for the symptomatic relief of allergic conditions and respiratory tract disorders associated with excessive mucus production. Levocetirizine, a selective third-generation non-sedative antihistamine, acts as a potent H1 receptor antagonist, effectively reducing symptoms of allergic rhinitis, urticaria, and other histamine-mediated conditions by inhibiting the release of histamine from mast cells. Ambroxol, a mucolytic agent, facilitates the clearance of mucus by stimulating the production of surfactant and enhancing mucociliary transport, thereby improving expectoration in patients with bronchitis, chronic obstructive pulmonary disease (COPD), and other respiratory ailments characterized by viscous or excessive mucus. The sustained-release (SR) formulation ensures a prolonged therapeutic effect, allowing for once-daily dosing and improved patient compliance. Laveta-A Capsule SR is indicated for patients requiring combined antihistaminic and mucolytic therapy to alleviate nasal congestion, cough, and sputum production associated with allergic and respiratory conditions. It should be used under medical supervision, with caution advised in patients with renal impairment or hypersensitivity to any component. Common adverse effects may include mild drowsiness, dry mouth, or gastrointestinal disturbances.